Total medical devices industry cross border deals worth $2.6bn were announced globally for November 2022, with WerfenLife’s $2bn acquisition deal with Immucor being the sector’s biggest investment, according to GlobalData’s deals database.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked a decrease of 42.7% over the previous month of $4.54bn and a drop of 11.9% when compared with the last 12-month average of $2.95bn.
In terms of number of cross border deals, the sector saw a drop of 33.33% with 42 deals in November 2022 when compared to the last 12-month average of 63 deals.
In value terms, North America led the activity with cross border deals worth $2.52bn in November 2022.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataMedical Devices industry cross border deals in November 2022: Top deals
The top five cross border deals accounted for 96.3% of the overall value during November 2022.
The combined value of the top five cross border deals stood at $2.5bn, against the overall value of $2.6bn recorded for the month.
The top five medical devices industry cross border deals of November 2022 tracked by GlobalData were:
1) WerfenLife’s $2bn acquisition deal with Immucor
2) The $449m private equity of 18% stake in Certara by Arsenal Capital Partners
3) Jolt Capital’s $20.16m private equity deal with BC Platforms
4) The $18.67m private equity of StageZero Life Sciences by GEM Global YieldSCS
5) Advanced MedTech Holdings and Lyndon Rive’s $12.4m venture financing deal with Sonomotion
